{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:28Z","timestamp":1792130728380,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302826"],"award-info":[{"award-number":["81302826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473280"],"award-info":[{"award-number":["81473280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program for Key Laboratory of Liaoning Province","award":["LZ2015027"],"award-info":[{"award-number":["LZ2015027"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.taap.2018.04.015","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T20:53:44Z","timestamp":1523652824000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro"],"prefix":"10.1016","volume":"348","author":[{"given":"Xiaoguang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqing","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-0719","authenticated-orcid":false,"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2018.04.015_bb0005","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2018.04.015_bb0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2013.05.030","article-title":"The metabolomic window into hepatobiliary disease","volume":"59","author":"Beyoglu","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2018.04.015_bb0015","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/hep.25918","article-title":"Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice","volume":"56","author":"Borude","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0020","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/dmd.113.056549","article-title":"Low dose of oleanolic acid protects against lithocholic acid-induced cholestasis in mice: potential involvement of nuclear factor-E2-related factor 2-mediated upregulation of multidrug resistance-associated proteins","volume":"42","author":"Chen","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2018.04.015_bb0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1124\/jpet.105.097758","article-title":"Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor","volume":"317","author":"Deng","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2018.04.015_bb0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.taap.2018.04.015_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.08.017","article-title":"Metabolic preconditioning protects BSEP\/ABCB11\u2212\/\u2212 mice against cholestatic liver injury","volume":"66","author":"Fuchs","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2018.04.015_bb0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4439(98)00053-2","article-title":"Molecular mechanisms of cholestasis: causes and consequences of impaired bile formation","volume":"1408","author":"Koopen","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2018.04.015_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.apsb.2015.01.005","article-title":"Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration","volume":"5","author":"Li","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.taap.2018.04.015_bb0055","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bcp.2009.06.026","article-title":"The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease","volume":"78","author":"Mencarelli","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2018.04.015_bb0060","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2010.12.037","article-title":"Insufficient bile acid signaling impairs liver repair in CYP27(\u2212\/\u2212) mice","volume":"55","author":"Meng","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2018.04.015_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bcp.2014.09.009","article-title":"Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor","volume":"92","author":"Meng","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2018.04.015_bb0070","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0075","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.xphs.2017.03.023","article-title":"Model systems for studying the role of canalicular efflux transporters in drug-induced cholestatic liver disease","volume":"106","author":"Stieger","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2018.04.015_bb0080","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0085","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2018.04.015_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2018.04.015_bb0095","doi-asserted-by":"crossref","first-page":"188101","DOI":"10.1103\/PhysRevLett.90.188101","article-title":"Energy landscape theory, funnels, specificity, and optimal criterion of biomolecular binding","volume":"90","author":"Wang","year":"2003","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.taap.2018.04.015_bb0100","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0105","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0110","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1039\/C4SC03416C","article-title":"Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration","volume":"6","author":"Yang","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.taap.2018.04.015_bb0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1751-2980.12378","article-title":"Role of farnesoid X receptor in cholestasis","volume":"17","author":"Yuan","year":"2016","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.taap.2018.04.015_bb0120","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/hep.25905","article-title":"Promotion of liver regeneration\/repair by farnesoid X receptor in both liver and intestine in mice","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2018.04.015_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2018.04.015_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tox.2017.01.007","article-title":"Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation","volume":"378","author":"Zhang","year":"2017","journal-title":"Toxicology"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X18301509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X18301509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T21:38:20Z","timestamp":1565300300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X18301509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":26,"alternative-id":["S0041008X18301509"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2018.04.015","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2018.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}